Thursday, January 28, 2016

FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4 - FDA Press Releases

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.

from Food and Drug Administration--Press Releases http://ift.tt/1QIomdb
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)